Document is current

Article History

Received: 22 March 2025

Accepted: 23 April 2025

First Online: 6 May 2025

Declarations

:

: The present study was in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: MC has received consulting and speaker fees from Boehringer-Ingelheim, Astra Zeneca, Daiichi Sankyo, Pfizer, and fees for Advisory Board from Boehringer-Ingelheim and Astra Zeneca. AZ has received consulting and speaker fees from Boehringer-Ingelheim, Astra Zeneca, CSL Behring, Daiichi Sankyo, Pfizer, and fees for Advisory Board from Daiichi Sankyo, Bayer, PIAM and Astra Zeneca. AZ was also local PI in ANNEXA-I and he is actually local PI in OCTAPLEX trial (4PCC high vs. low dose in DOAC-ICH pts). DT was National Coordinator Trial ANNEXA-I and had received speaker honoraria and fess for advisory Board from Astra Zeneca.